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Introduction
Primary percutaneous coronary intervention (PPCI) is
defined as angioplasty with or without stent implantation,
with no prior or concomitant fibrinolytic therapy 
1. PPCI
compared with medical therapy is a method of choice in the
treatment of acute myocardial infarction with ST-segment
elevation (STEMI), significantly reducing mortality and rei-
schemia 
1. Implantation of bare metal stent (BMS) on the
culprit lesion in STEMI is associated with a reduced inci-
dence of target vessel revascularization (TVR), but is not as-
sociated with a reduced mortality and reinfarction compared
to primary balloon dilatation of a culprit lesion 
2. Although
some authors question the rate of restenosis of BMS in
STEMI due to different patophysiological process, plaque
rupture and formation of thrombus, restenosis in STEMI pa-
tients occurs in more than 20% of patients 
2, 3. The advantage
of drug-eluting stents (DES) compared to BMS to prevent
coronary restenosis in a variety of patients is proved in elec-
tive procedures 
4, 5, while in the treatment of STEMI is still
controversial, due to the lack of randomized studies with a
duration of follow-up more than one year. Thus, at the mo-
ment there is a debate weather DES should be used in PPCI
routinely.
STEMI is an independent stent thrombosis (ST) pre-
dictor both for BMS and DES especially when the complex
lesions are treated (ostial and bifurcation lesions) 
6–9. This
can be explained by prothrombotic state, hemodynamic
changes (cardiogenic shock), stent apposition and insuffi-
cient expansion of the stent. Also, it is shown on autopsy that
DES postpones endothelization of ruptured plaque, which is
a primary cause of late ST, with persistent fibrin deposition
compared to BMS 
10. Because of a longer duration of arterial
healing of ruptured plaque (> 1 year) compared to stable
plaque 
8, safety of DES in STEMI patients cannot be deter-
mined in short term studies. Observational studies have indi-
cated the existence of an increased risk in emerging late and
very late (> 1 year) ST associated with the use of the first
generation of DES 
11, especially for indications that are dif-
ferent from those approved by the U.S. Food and Drug Ad-
ministration (FDA) (''off-label'' DES indications), which in-
cludes STEMI 
12. However, recent results from randomized
trials, meta-analysis and registries, with short and intermedi-
ate duration of follow-up have demonstrated that the selec-
tion of the second generation of DES in STEMI is safe since
there is no difference in mortality and reinfarction compared
to the BMS group with a significant reduction in TVR.
Randomized studies using sirolimus-eluting stents
In a randomized prospective study, Single High Dose
Bolus Tirofiban and Sirolimus Eluting Stent vs Abciximab
and Bare Metal Stent in Myocardial Infarction (STRAT-
EGY) 
13, with follow-up of 8 months, the primary objectives
(death, myocardial infarction, stroke and TVR) were signifi-
cantly lower in the sirolimus-eluting stents (SES) group than
in the BMS group (18% vs 32%, p = 0.04) primarily due to
less TVR in the SES group compared to the BMS group (7%
vs 20%,  p =  0.01). The limitations of the study were: in-
volvement of single center, small sample size (even though
only 12% of consecutive patients were not enrolled in the
study) and the same choice of stent and glycoprotein IIb/IIIa.
To overcome the above limitations, the same group of
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Dose Bolus Tirofiban vs Abciximab With Sirolimus-eluting
Stent or Bare Metal Stent in Acute Myocardial Infarction
Study (MULTISTRATEGY) trial 
14, where a sample of 745
patients were first randomly assigned to either abciximab or
tirofiban and then to SES or BMS. After 8 months, major
adverse cardiac events (MACE), composite of death of any
cause, reinfarction, and clinically driven TVR, was signifi-
cantly different in the SES compared to the BMS group
(7.8% vs 14.5%, p = 0.004), also due to lower rate of TVR
(3.2% vs 10.2%, p < 0.001) 
14. Composite endpoint of death,
reinfarction and ST was comparable between the two groups
at the end of 8 months follow-up 
14. ST did not differ signifi-
cantly between the two groups even though dual antiplatelet
therapy was given in SES group for at least 3 months and
sensitive classification (definite/probable/possible) of ST
was used 
14.
Similar results were seen in the randomized Trial to As-
sess the Use of the Cypher Stent in Acute Myocardial In-
farction Treated with Balloon Angioplasty (TYPHOON)
study, which included 712 STEMI patients with a follow-up
period of 12 months 
15. The primary endpoint-target vessel
failure (defined as target-vessel-related death, reinfarction or
TVR) was significantly reduced in the SES than in the BMS
arm (7.3% vs14.3%, p = 0.004) which was again primarily
due to reduced rates of TVR in the SES compared to the
BMS group (5.6% vs 13.4%, p < 0.001) 
15. The rate of acute
and subacute ST did not differ between the two arms after
the first year of follow-up 
15. Recently the same group of
authors presented that after 4 years there were no significant
differences in definite or probable ST, freedom from rein-
farction and cardiac death in the SES group compared to the
BMS group, while freedom from target lesion revasculariza-
tion (TLR) was significantly better in the SES group 
16.
Randomized trials using paclitaxel-eluting stents in
STEMI
The Paclitaxel-eluting Stents vs Bare Metal Stents in
Myocardial Infarction with ST-segment Elevation (PAS-
SION) study that included 619 STEMI patients randomized
to paclitaxel-eluting stent (PES) or BMS 
17, with a 12-month
follow-up period, did not show a statistically significant dif-
ference in primary events (death, myocardial infarction,
TVR) between PES and BMS groups (12.8% vs 8.8%, p =
0.12) 
17. TVR between the PES and BMS groups was not
statistically significant (5.3% vs 7.8%), probably due to a
low percentage of patients with diabetes (11%), more limited
selection of angiographic characteristics (larger vessel di-
ameter) and the absence of angiographic follow-up. The per-
centage of ST was not statistically significant between the
PES and BMS groups after one year 
17. At 5 years, the occur-
rence of the composite of cardiac death, recurrent myocardial
infarction, or TLR was comparable in the PES and BMS arm
(18.6% vs 21.8%, p = 0.28), as also the incidence of definite
or probable ST (4.2% vs 3.4%, p = 0.68) 
18.
Safety and efficacy of PES stents in STEMI has been
proved so in far the largest published randomized trial Har-
monizing Outcomes with Revascularization and Stents in
AMI (HORIZONS-AMI), involving 3006 STEMI patients 
19.
After 12 months, the PES group compared to the BMS group
had a significantly lower TLR (4.5% vs 7.5%, p = 0.002),
and TVR (5.8% vs 8.7%, p = 0.006). The mortality and ST
was similar between the PES and BMS group 
19. At 3 years,
the major findings from the stent part of the trial were that
the PES seemed safe in STEMI with a significantly lower is-
chaemia-driven TVR in the PES arm 
20. There were no sig-
nificant differences in the rates of death, reinfarction,
stroke 
20. ST was similar in both groups – around 5% 
20. In
the intravascular ultrasound substudy of HORIZONS-AMI,
it was shown that acute stent malapposition was similar in
PES and BMS treated lesions, but late acquired stent malap-
position was more common in PES treated lesions and it was
due to positive remodeling and plaque/thrombus resolu-
tion 
21. However, either acute stent malapposition or late ac-
quired stent malapposition were not associated with adverse
cardiac events at one year 
21. A recent optical coherence to-
mography study shows that PES significantly reduces neoin-
timal hyperplasia, but results in higher rates of uncovered
and malapposed stent struts and different healing response of
the ruptured plaque at a 13-month follow-up 
22. Still, studies
are needed to determine the relationship between these opti-
cal coherence tomography observations and long-term ad-
verse clinical events.
Randomized trials using the second generation of
drug-eluting stents in STEMI
Since the first generation of SES and PES raised safety
concerns after the first year 
23, 24, second generation of DES
brought novel improved biocompatible and biodegradable
polymers 
25, new antiproliferative agents and designs which
might increase biocompatibility therefore improving long
term efficacy and safety profile. Thus, patients with STEMI
might benefit from the second generation of DES 
26.
Drug Elution and Distal Protection in Acute Myocardial
Infarction (DEDICATION) trial included 626 patients from
the two centers 
27. The primary endpoint was the loss of lu-
minal diameter in the infarct-related lesion determined using
quantitative coronary angiography at 8 months. Stents im-
planted in the DES group were SES in 47%, PES in 40% and
zotarolimus-eluting stents in 13% 
27. While the primary end-
point was in favor of DES (late lumen loss 0.06 ± 0.66 mm
vs 0.47 ± 0.69 mm, p < 0.001), there was a strong tendency
toward a higher cardiac death in the DES group (4.2% vs
1.6%, p = 0.09) 
27. TLR was lower in the DES arm (5.1% vs
13.1%, p = 0.001), while ST rates were similar in the two
groups (2.0% vs 2.6%, p = 0.72) 
27.  Inclusion criteria in this
trial were less strict with a higher rate of patients with com-
plex lesions, older patients, more stents per patient implanted
and stented longer segments of the coronary arteries com-
pared to the other studies 
27. After 3 years the rate of all-
cause mortality was not statistically different while the car-
diac death was significantly higher in DES group (6.1% vs
1.9%, p = 0.01) which was contrary to previous studies 
28.
MACE was still significantly higher in the BMS arm (18.2%
vs 11.5%, p = 0.02) due to a higher TVR 
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The Evaluation of the Xience-V Stent in Acute Myo-
cardial Infarction (EXAMINATION) trial presented novel
data with the second generation of cobalt-chromium evero-
limus-eluting stent (CoCr-EES) in STEMI 
29. The author
stated that “all-comers” design of the study with wide in-
clusion and less exclusion criteria will be a representative
sample for “real world” population. Patients were random-
ized 1:1 on either CoCr-EES or BMS 
29. There were no dif-
ferences in primary endpoint (all-cause death, reinfarction
or revascularization), cardiac death and reinfarction be-
tween the two groups. Although the study failed to reach its
primary endpoint, there were benefits in using EES since
TVR and TLR were significantly lower in CoCr-EES com-
pared to BMS arm, while definite ST was significantly
higher in the BMS group (1.9% vs 0.5%, p = 0.01) 
29. How-
ever, this trial was not powered to show differences of ST
and thus whether those findings are real or attributable to
chance remain uncertain 
29, 30. Still, these results are similar
to the result of recent meta-analysis that CoCr-EES had
also reduced ST compared with BMS 
30. These results sup-
port the safety and efficacy of CoCr-EES in a representa-
tive sample of STEMI patients especially in preventing the
early ST rate with the use of second generation DES 
29. A
recent nonrandomized study, which evaluated the safety
and effectiveness of the second generation of CoCr-EES in
patients with acute myocardial infarction (AMI) with a pa-
tient without AMI showed at 1 year low clinical event rates
in these two groups 
31. Comparing with elective procedures,
the rates of  ST at one year were 1.08% vs. 0.85% and late
ST (30 days-1 year) were 0.31% vs 0.47%, (AMI vs non-
AMI, all p = ns) 
31. Even though the sample size of AMI
patients was small, low ST rates associated with CoCr-EES
use in both non-AMI and AMI patients in this study are
consistent with previous randomized controlled trials such
as Clinical Evaluation of the XIENCE V Everolinus
Eluting Coronary Stent System (SPIRIT) IV 
32 and EX-
AMINATION 
31.
A recent meta analysis has presented that CoCr-EES is
associated with a significant reduction in definite ST com-
pared with BMS and other first and second generation DES
including PES, SES, resolute zotarolimus and phosphoryl-
choline polymer-based zotarolimus eluting stent at a 1-year
follow-up 
25. In the same meta-analysis it was presented that
only CoCr-EES showed a significant reduction of definite ST
compared with BMS at a 2-years follow-up 
25. The authors
stated that the results are consistent with the result of ex-
perimental studies, which compared EES with BMS, show-
ing that a lower rate of ST in EES is due to the design and
material (reduced stent strut thickness, use of a cobalt-
chromium and platinum-chromium alloys instead of stainless
steel) and durable, fluorinated and thromboresistant polymer
25. It is of note, that even SES were also associated with sig-
nificantly lower 1-year rates of definite ST compared to the
BMS, but it was not maintained at 2 year follow-up 
25. How-
ever, larger and adequately powered randomized trials with
longer follow-up in STEMI setting are needed to eliminate
concerns of safety of these devices compared to BMS and
with other DES.
The latest Comparison of Biolimus Eluted From an
Erodible Stent Coating With Bare Metal Stents in Acute ST-
Elevation Myocardial Infarction (COMFORTABLE AMI)
trial included STEMI patients randomly assigned on a 1:1
basis to treatment with biolimus-eluting stents (BES) from a
biodegradable polylactic acid polymer or BMS 
33. The pri-
mary endpoint of the study was the device-oriented compos-
ite of cardiac death, reinfarction, and ischemia-driven TLR at
1 year 
33. Major adverse cardiac events at 1 year occurred in
4.3% of patients receiving BES and 8.7% patients receiving
BMS (p = 0.004) 
33. It was due to lower risk of target vessel
reinfarction (p = 0.01) and ischemia driven TLR (p = 0.001)
in patients receiving BES compared with those receiving
BMS. The rates of cardiac death were not significantly dif-
ferent while ST occurred in 5 patients treated with BES and
12 patients (p = 0.10) treated with BMS 
33. The second gen-
eration DES–BES with biodegradable polymers provide
controlled drug release with subsequent degradation of
polymer contrary to durable polymer coatings for drug re-
lease of the first generation DES, which might be a trigger
for the late ST 
26, 34. This might improve long-term clinical
outcomes beyond 1 year by reducing the risk of ST by 80%
compared to the first generation DES 
26, 33, 34.
Similar to patients with stable angina, no randomized
studies have demonstrated the effectiveness of DES in low-
ering the rates of cardiac death and myocardial infarction
compared to BMS arms in STEMI patients. Also, current tri-
als do not bring enough evidence concerning benefits of DES
compared to BMS in STEMI patients as in the elective pro-
cedures when DES is proved to be more effective (long le-
sions, small vessels, diabetic patients). On the other hand,
these randomized studies clearly indicate the safe use of DES
in STEMI patients and a reduced TVR in the DES group,
without a significant difference in cardiac death, reinfarction
and ST after 1-year follow-up. Meta-analyses of these ran-
domized studies also present that DES significantly reduce
TVR compared to BMS, without an increase in death, rein-
farction, or ST within 1 
35 and 2 years of the index proce-
dure 
25, 26, 37. However, a long-term analysis at 3 to 5 years
after the procedure showed that the use of the first generation
DES in STEMI is associated with an excess of very late
thrombotic complications 
23 which occurred more likely in
the DES group compared to the BMS arm.
The second generation DES might overcome very late
thrombotic complication due to novel improved biocompati-
ble and biodegradable polymers, new antiproliferative agents
and designs, as a result patients with STEMI might benefit
from these devices 
25, 26, 34, 38. Both Examination and Com-
fortable trials are not statistically powered neither have long-
time follow-up to provide definite answer about safety of
second generation DES. To be statistically powered to detect
the difference in low-frequency events such as very late ST
between available DES, there is a need for randomized trial
which would include as many as 10,000 patients in STEMI
setting. Consequently, the results from observational data,
meta analysis and randomized trials between different DES
devices in stable angina and acute coronary syndrome pre-
sented that second generation DES are more effective andVolumen 71, Broj 9 VOJNOSANITETSKI PREGLED Strana 873
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with increased safety compared with either BMS or the first
generation of DES, which should lead to greatly improved
outcomes in patient with AIM 
24–26, 34, 39–41.
Conclusion
The efficacy of DES compared to BMS in reducing in-
stent restenosis and repeat intervention within one year was
shown in many randomized studies, registries and meta-
analysis, therefore further studies comparing the efficacy of
DES to BMS might not be needed in the setting of AMI.
Although no significant difference in mortality, reinfarction
and ST was shown in DES compared to BMS, late safety is-
sues with DES are mostly related to the first generation of
DES. Observational data, meta-analysis and randomized tri-
als with the second generation of DES devices have showed
better efficacy with increased safety compared with either
BMS or the first generation of DES leading to the conclusion
that the second generation of DES should be the “first
choice” in STEMI setting.
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